DrugInfoSys

Oxaliplatin

Drug #1818

Oxaliplatin is the platinum-containing complex similar to cisplatin. This agent was recently approved for use as a second line therapy in metastatic colorectal cancer. Neurotoxicity is its dose limiting side effect and characterized by peripheral sensory neuropathy.

← Previous drugNext drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 397.3 · Non-proprietary name: Oxaliplatin.

Molecular structure of Oxaliplatin

Pharmacokinetics

Distribution: Oxaliplatin has a plasma protein binding is 80 %.

Elimination: renal excretion is 50 %.

Advertisement

Indications

Oxaliplatin is primarily indicated in conditions like Cervical carcinoma, Cyclical benign breast disease, Germ cell tumors, Neurogenic bladder, Ovarian cancer.

Oxaliplatin is also indicated for secondary conditions like Severe nausea, vomiting (acute attacks).

Contraindications

Oxaliplatin is contraindicated in conditions like Peripheral neuropathy, Pregnancy, Breast feeding.

Dosage

Oxaliplatin's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
85 mg/sq. metre85 mg/sq. metre—IVEvery 2 weeks
130 mg/sq. metre130 mg/sq. metre—IVEvery 3 weeks
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

7 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Oxaliplatin in overdosage may give rise to further complications which include Bone marrow depression .

Oxaliplatin is known to cause more or less tolerable side effects which are usually transient. These include Alopecia, Gastrointestinal disturbances, Myelosuppression, Nausea and vomiting, Ototoxicity , Sensory peripheral neuropathy.

Warnings / Precautions

Oxaliplatin in combination with fluorouracil and folinic acid, should be considered first-line treatment for advanced colorectal cancer only in patients with metastases which are confined to liver and which could be resected following treatment. Oxaliplatin causes mild renal impairment, so manufacturers advise avoid if creatinine clearance less than 30 ml/min.

Interference in Pathology

Oxaliplatin may interfere in the diagnosis of Liver Function Test (LFT) , Monitoring of hematologic profile, Monitoring of ALT AND AST level.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inf
100 mg100 mg/ml50 mg50 mg/ml
Inj
100 mg50 MG

Drug Classification

  1. 1.8.2 — Cytotoxic (anti-neoplastic) drugs

Manufacturers